7月17日，微创医疗盘中下跌6.74%，报6.64港元，成交额1.17亿港元。公司此前连涨两日后出现大幅回吐。
消息面上，公司7月15日公告旗下苏州微创骨科与天智航签署意向书，拟出售上海微创骨科82.29%股权，对价以天智航发行新股方式支付。该标的为公司海外骨科核心运营主体，覆盖美、日、欧市场，年收入约2.35亿美元。市场在初期利好消化后分歧加剧：一方面，出售核心海外资产或反映公司偿债压力及半年报业绩承压；另一方面，天智航作为尚未盈利的科创板企业，其换股对价的实际变现能力存在不确定性。此外，交易尚处初步磋商阶段，具体条款待定，摩根大通此前已连续减持公司股份，短线获利资金离场进一步放大回调幅度。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.